COMPANY

MingSight Pharmaceuticals

HQ: San Diego, CA source · mingsight.com ↗

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: CLL (Chronic Lymphocytic Leukemia) SLL (Small Lymphocytic Lymphoma) Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Aggressive Lymphoma Relapsed or Refractory B-cell Lymphoma Diffuse Large B-cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma MS-553

4Trials (company is sponsor)

Timeline

2026-07 Trial start I: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL source ↗
Feb 6, 2023 Trial start Phase 1/Phase 2: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma source ↗
May 25, 2018 Trial start Phase 1/Phase 2: A Study Of The Selective PKC-β Inhibitor MS- 553 source ↗
2015-04 Trial start Phase 1: A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers source ↗

Upcoming milestones

2028-09 (ESTIMATED) · I · A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL · NCT06979076

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06979076	A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL	I	Not yet recruiting	2026-07	2028-09 (estimated)
NCT03492125	A Study Of The Selective PKC-β Inhibitor MS- 553	Phase 1/Phase 2	Terminated	May 25, 2018	Nov 28, 2023 (actual)
NCT05720052	A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2	Terminated	Feb 6, 2023	Nov 28, 2023 (actual)
NCT02406989	A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers	Phase 1	Completed	2015-04	2015-08 (actual)